| Literature DB >> 28095714 |
Pieter Hindryckx1, Gregor Novak2, Antonio Costanzo3, Silvio Danese4,5.
Abstract
INTRODUCTION: Skin manifestations are common in patients with inflammatory bowel diseases (IBD) and can be part of a concomitant illness with a shared genetic background, an extra-intestinal manifestation of the disease, or a drug side-effect. Areas covered: We provide a practical overview of the epidemiology, pathogenesis, diagnosis, therapeutic approach and prognosis of the most frequent disease-related and drug-induced cutaneous manifestations in IBD, illustrated by cases encountered in our clinical practice. Among the most frequently encountered IBD-related lesions are erythema nodosum, pyoderma gangrenosum and Sweet's syndrome. Common skin manifestations with a strong association to TNF antagonists are local injection site reactions, psoriasiform lesions, cutaneous infections, vasculitides and lupus-like syndromes. In addition, we discuss the relation of thiopurines and TNF antagonists with the risk of skin cancer. Expert commentary: We hope this review will help caretakers involved in the management of IBD patients to recognize the lesions and to manage them in close collaboration with a dedicated dermatologist.Entities:
Keywords: Skin lesions; cutaneous; drug-induced; extra-intestinal; inflammatory bowel disease
Mesh:
Substances:
Year: 2017 PMID: 28095714 DOI: 10.1080/17474124.2017.1283985
Source DB: PubMed Journal: Expert Rev Gastroenterol Hepatol ISSN: 1747-4124 Impact factor: 3.869